Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart Plus Anlotinib Versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT07881900Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Sun Yat-sen University. Started Jun 2025; status: active, not recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT07881900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881900.